These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 16856889)
21. Bortezomib as therapy for mixed humoral and cellular rejection: should it be first line? Lee I; Constantinescu S; Gillespie A; Swami A; Birkenbach M; Leech S; Silva P; Karachristos A; Daller JA; Sifontis NM Clin Transpl; 2009; ():425-9. PubMed ID: 20524309 [No Abstract] [Full Text] [Related]
22. Long-term remission in a patient with hepatosplenic gammadelta T cell lymphoma treated with bortezomib and high-dose CHOP-like chemotherapy followed by autologous peripheral stem cell transplantation. Otrock ZK; Hatoum HA; Salem ZM; Tawil A; Mahfouz RA; Zaatari GS; Bazarbachi A Ann Hematol; 2008 Dec; 87(12):1023-4. PubMed ID: 18587577 [No Abstract] [Full Text] [Related]
23. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Lonial S; Richardson PG; San Miguel J; Sonneveld P; Schuster MW; Bladé J; Cavenagh J; Rajkumar SV; Jakubowiak AJ; Esseltine DL; Anderson KC; Harousseau JL Br J Haematol; 2008 Oct; 143(2):222-9. PubMed ID: 18713253 [TBL] [Abstract][Full Text] [Related]
24. Proteasome inhibition for treatment of multiple myeloma: clinical update. Stadtmauer EA J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S10-5. PubMed ID: 19795531 [TBL] [Abstract][Full Text] [Related]
25. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Aghajanian C; Blessing JA; Darcy KM; Reid G; DeGeest K; Rubin SC; Mannel RS; Rotmensch J; Schilder RJ; Riordan W; Gynecol Oncol; 2009 Nov; 115(2):215-20. PubMed ID: 19712963 [TBL] [Abstract][Full Text] [Related]
33. Bortezomib for antibody mediated rejection treatment: experience at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City. Leyva S; Marino-Vázquez LA; Reyes-Loaeza JA; Vega O; Uribe-Uribe N; Alberú J; Morales-Buenrostro LE Clin Transpl; 2009; ():369-76. PubMed ID: 20524300 [TBL] [Abstract][Full Text] [Related]
34. M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis. Riccioni R; Senese M; Diverio D; Riti V; Buffolino S; Mariani G; Boe A; Cedrone M; Lo-Coco F; Foà R; Peschle C; Testa U Br J Haematol; 2007 Oct; 139(2):194-205. PubMed ID: 17897295 [TBL] [Abstract][Full Text] [Related]
35. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma. El-Cheikh J; Michallet M; Nagler A; de Lavallade H; Nicolini FE; Shimoni A; Faucher C; Sobh M; Revesz D; Hardan I; Fürst S; Blaise D; Mohty M Haematologica; 2008 Mar; 93(3):455-8. PubMed ID: 18287132 [TBL] [Abstract][Full Text] [Related]
36. Proteasome inhibitors in pediatric cancer treatment. Bachmann AS Hawaii Med J; 2008 Sep; 67(9):247-9. PubMed ID: 18853901 [TBL] [Abstract][Full Text] [Related]
38. A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience. Engel RH; Brown JA; Von Roenn JH; O'Regan RM; Bergan R; Badve S; Rademaker A; Gradishar WJ Cancer Invest; 2007 Dec; 25(8):733-7. PubMed ID: 17952740 [TBL] [Abstract][Full Text] [Related]
39. Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma. Zangari M; Guerrero J; Cavallo F; Prasad HK; Esseltine D; Fink L Haematologica; 2008 Jun; 93(6):953-4. PubMed ID: 18515882 [No Abstract] [Full Text] [Related]
40. Bortezomib and extramedullary disease in multiple myeloma: the shine and dark side of the moon. Ali R; Ozkalemkas F; Ozkan A; Ozkocaman V; Ozcelik T; Ozan U; Kurt M; Tunali A Leuk Res; 2007 Aug; 31(8):1153-5. PubMed ID: 16945413 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]